A
LIVE

Serial Number

97159481

Owner

ADELA CANADA, INC.

Attorney

Ryan S. Hilbert

First Use Date

Jul 28, 2025

Filing Date

Dec 7, 2021

Add to watchlist:

No watchlists yet
View on USPTO

A Trademark

Serial Number: 97159481 • Registration: 8128345

A is a trademark filed by ADELA CANADA, INC. on December 7, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ADELA CANADA, INC. (3 trademarks)

MaRS South Tower
Toronto, Ontario M5G2C4 , CA

Entity Type: 03

Trademark Details

Filing Date

December 7, 2021

Registration Date

February 3, 2026

First Use Anywhere

July 28, 2025

First Use in Commerce

July 28, 2025

Published for Opposition

October 11, 2022

Goods & Services

Providing medical research information regarding results of testing for various medical conditions; Providing scientific analysis and information regarding the results of laboratory testing in the field of various medical conditions; Laboratory testing services, namely, clinical processing of medical diagnostic testing kits; Medical research; Scientific research for medical purposes in the field of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; Providing temporary use of non-downloadable software for use in creating, displaying, sharing and storing information, test results and data in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; Providing online computer databases featuring medical research information in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases

Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying advanced analytics; Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying machine learning technology; Diagnostic assays, reagents, and nucleotides for medical or clinical purposes

Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring, and reporting services; Consulting services in the fields of diagnostic medical testing; Providing medical information, consultancy and advisory services; Providing medical testing services and information in the fields of cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases for diagnostic or treatment purposes; Medical testing services, namely, diagnostic testing services for detecting cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases by identifying and analyzing biomarkers for diagnostic or treatment purposes; Providing screening, detection, and monitoring services for cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases

Blood collection kit comprised of blood collecting tubes; Blood testing apparatus; Diagnostic apparatus for medical purposes, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in liquid biopsy testing; Diagnostic tests comprising medical apparatus and instruments, namely, liquid biopsy testing systems; Medical diagnostic testing kits containing sterile medical specimen collection tools in the nature of lancets for the collection of blood for use in testing and for monitoring various medical conditions, and also including instructions and return shipping packaging; Testing kits containing medical laboratory research instruments for taking samples of human blood and body fluids for use in detecting cancer and other prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 3, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 3, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 14, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 14, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 4, 2025 SUPC
USE AMENDMENT FILED
Dec 3, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 3, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2025 EXRA
SOU EXTENSION 5 GRANTED
Oct 29, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 29, 2025 AITU
SOU TEAS EXTENSION RECEIVED
Jun 2, 2025 EEXT
SOU EXTENSION 5 FILED
Jun 1, 2025 EXT5
SOU EXTENSION 4 GRANTED
Nov 4, 2024 EX4G
SOU EXTENSION 4 FILED
Nov 4, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 3, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jun 5, 2024 EX3G
SOU EXTENSION 3 FILED
Jun 5, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 5, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 5, 2023 EXRA
SOU EXTENSION 2 GRANTED
Dec 2, 2023 EX2G
SOU EXTENSION 2 FILED
Dec 2, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 2, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 7, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jun 5, 2023 EX1G
SOU EXTENSION 1 FILED
Jun 5, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 5, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 6, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 11, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 11, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 21, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 8, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 2, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 1, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 1, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 2, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 2, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 2, 2022 CNRT
ASSIGNED TO EXAMINER
Feb 22, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 13, 2021 NWOS
NEW APPLICATION ENTERED
Dec 10, 2021 NWAP